Axplora- The partner of choice for complex APIs.
01 1Farmabios S.p.A.
02 2AX Pharmaceutical Corp
03 1Catalent Micron Technologies, Inc.
04 1Cipla Ltd.
05 1Curia Spain S.A.U.
06 1Curia Wisconsin, Inc.
07 1Fagron Inc
08 1Pfizer Asia Manufacturing Pte Ltd
09 1STERLING SPA
10 1ScinoPharm Taiwan Ltd.
11 1Shandong Anhong Pharmaceutical Co., Ltd.
12 2Sterling Chemical Malta Ltd
13 1Sterling S.p.A.
14 1Symbiotica Speciality Ingredients Sdn. Bhd.
15 1Viatris Pharmaceuticals LLC
01 7EXEMESTANE
02 9Exemestane
03 1Exemestrane
01 2Canada
02 1China
03 1Germany
04 1India
05 2Italy
06 1Malaysia
07 2Malta
08 1Netherlands
09 1Taiwan
10 5U.S.A
Axplora- The partner of choice for complex APIs.
NDC Package Code : 46439-8746
Start Marketing Date : 2012-07-19
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
NDC Package Code : 62157-091
Start Marketing Date : 2015-05-22
End Marketing Date : 2020-12-31
Dosage Form (Strength) : POWDER (49.5g/50g)
Marketing Category : BULK INGREDIENT FOR HUMAN P...
NDC Package Code : 53104-7666
Start Marketing Date : 2016-01-01
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (25kg/25kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 64181-0005
Start Marketing Date : 1999-10-21
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (20kg/20kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 51552-1619
Start Marketing Date : 2021-10-07
End Marketing Date : 2026-03-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT FOR HUMAN P...
NDC Package Code : 49386-026
Start Marketing Date : 2019-12-24
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (10kg/10kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 59057-007
Start Marketing Date : 2018-02-27
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT FOR HUMAN P...
NDC Package Code : 59057-008
Start Marketing Date : 2018-02-27
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT FOR HUMAN P...
NDC Package Code : 64918-0621
Start Marketing Date : 2014-07-24
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 52128-134
Start Marketing Date : 2006-04-06
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
A Exemestane manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Exemestane, including repackagers and relabelers. The FDA regulates Exemestane manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Exemestane API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Exemestane manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Exemestane supplier is an individual or a company that provides Exemestane active pharmaceutical ingredient (API) or Exemestane finished formulations upon request. The Exemestane suppliers may include Exemestane API manufacturers, exporters, distributors and traders.
click here to find a list of Exemestane suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Exemestane as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Exemestane API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Exemestane as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Exemestane and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Exemestane NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Exemestane suppliers with NDC on PharmaCompass.
We have 13 companies offering Exemestane
Get in contact with the supplier of your choice:
LOOKING FOR A SUPPLIER?
